- known hypersensitivity to colchicine or its excipients - severe diarrhea - patients who cannot take oral therapy - pregnant and lactating patients - patients with severe cardiac, renal insufficiency (creatinine clearance (ccl) <30 ml / min) - patients with kidney or liver damage [(ast or alt> 5 times the normal limits in international units (uln)]; or are taking cyp3a4 enzyme - p glycoprotein inhibitors. - known other clinical condition that contraindicates colchicine and cannot be treated or solved according to the judgement of the clinician - neutrophils <1.000 / mmc - platelets <50.000 / mmc - bowel diverticulitis or perforation - patients already in icu or requiring mechanical ventilation - patients receiving tocilizumab - patients already enrolled in other clinical trials

- known hypersensitivity to colchicine or its excipients - severe diarrhea - patients who cannot take oral therapy - pregnant and lactating patients - patients with severe cardiac, renal insufficiency (creatinine clearance (ccl) <30 ml / min) - patients with kidney or liver damage [(ast or alt> 5 times the normal limits in international units (uln)]; or are taking cyp3a4 enzyme - p glycoprotein inhibitors. - known other clinical condition that contraindicates colchicine and cannot be treated or solved according to the judgement of the clinician - neutrophils <1.000 / mmc - platelets <50.000 / mmc - bowel diverticulitis or perforation - patients already in icu or requiring mechanical ventilation - patients receiving tocilizumab - patients already enrolled in other clinical trials